BioMimetic raises $45 million from stock offering, plans to fund product development

By · July 21, 2010 · No comments
Biologics · Tagged: , , ,

FRANKLIN, Tenn. (AP) - BioMimetic Therapeutics Inc. said it generated about $45 million in proceeds after expenses from the sale of about 5.6 million shares in a public offering.

The Franklin, Tenn., biotechnology company, which makes devices for musculoskeletal injuries, said Tuesday that underwriters exercised their option to buy about 642,000 additional shares. The company sold the stock at $8.50 per share.

BioMimetic will use proceeds from the offering for general corporate purposes and to develop and support its product pipeline. That includes the Augment Bone Graft, a synthetic material for bone fusing with the goal of stimulating a permanent connection between broken bones, and sports medicine products.

J.P. Morgan Securities Inc. acted as sole book-running manager of the offering, with Canaccord Genuity and Wedbush PacGrow Life Sciences serving as co-managers.

Posted By

Josh Sandberg has been recruiting specifically in the musculoskeletal industry for over 8 years. Throughout this time, he has been able to have a positive impact on his client’s businesses. With an educational background in Business Management, Josh is adept to discern which people will be the best fit for the company he is searching for by understanding how candidates will incorporate with the company’s culture and operational nuances. His experience as an executive in a start-up business has granted him the ability to understand what is takes to thrive in a hands–on environment, where desire and dedication are paramount for success.
←
→

© 2012 OrthoSpineNews